A retrospective multi-center study analyzed the use of vasopressin (VA) and norepinephrine (NE), two distinct pressors, in 58 neonates with warm septic shock across three Canadian Level-III NICUs between 2015 and 2020.

The study aimed to provide practical insights into the use of these agents, excluding neonates who received both.

A key demographic difference was observed: the VA group had a significantly higher mean gestational age (GA 27.1±4.1 weeks) and birth weight compared to the NE group (GA 24.9±2.8 weeks, p=0.015).

The findings suggest that the use of vasopressin in neonatal septic shock appears promising. However, the researchers emphasize the need for further prospective studies to explore VA’s potential as a first-line agent.

These future investigations should focus on detailing its specific cardiopulmonary effects and safety profile in this vulnerable population to establish clearer guidelines for its therapeutic use alongside or instead of traditional pressors like norepinephrine.

Read More